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There is a pressing need to identify new drug targets and novel approaches for treatment of non-small-cell lung carcinoma (NSCLC).
Members of the epidermal growth factor receptor (EGFR) and Met receptor families have been identified as important molecular
targets for NSCLC. Two EGFR tyrosine kinase inhibitors (TKIs; erlotinib and gefitinib) are in current clinical use, but a majority of
patients do not respond to these targeted therapies. We used receptor TK (RTK) capture arrays to identify receptors active in
NSCLC cell lines. As Met and ErbBs were active, we explored the potential therapeutic advantage of combined targeting of Met with
ErbB receptor family inhibitors for treatment of NSCLC. We found that Met physically interacts with both EGFR and Her2 in a
NSCLC cell line with overexpression/overactivation of Met. Combined use of a dual EGFR/Her2 inhibitor with a Met inhibitor yields
maximal growth inhibition compared with the use of EGFR and/or Met inhibitors. This suggests that simultaneous inhibition of
multiple RTKs may be needed to effectively abrogate tumour cell growth. Phosphoproteomic analysis by RTK capture arrays may be
a valuable tool for identifying the subset of tumours with functional receptor activation, regardless of mechanism.
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Non-small-cell lung cancer (NSCLC) accounts for the majority of
all lung cancer cases and, with poor prognosis and low cure rate, is
a leading cause of cancer mortality. Tyrosine kinase inhibitors
(TKIs) have emerged as an important class of drugs for the
treatment of NSCLC. Gefitinib (Iressa) and erlotinib (Tarceva) are
the two US FDA-approved epidermal growth factor receptor
(EGFR)-specific TKIs that have shown clinical benefit in treating
NSCLC. They appear to work, in part, by inhibiting the effects of
gain-of-function mutations in EGFR, but patients with tumours
lacking mutations benefit as well (Sordella et al, 2004; Mukohara
et al, 2005). Gain-of-function mutations are clustered around the
catalytic domain of EGFR and are either single amino-acid
substitutions or small insertions/deletions. However, not all
patients carrying activating mutant EGFR benefit from TKI
therapy and almost all acquire resistance within a year after initial
response (Haber et al, 2005; Riely et al, 2006; Sharma et al, 2007).
A major mechanism of resistance to TKI-based therapy is the
development of a second site mutation (T790M) in EGFR causing a
conformational change that inhibits effective binding of the kinase
inhibitors to the ATP pocket (Liu et al, 2006). Another secondary
mutation (D761Y) in EGFR was identified in an NSCLC brain
metastasis originating from a primary tumour that initially
responded to gefitinib-based therapy (Balak et al, 2006). Another
route for escape from TKI therapy is the acquired amplification of
the hepatocyte growth factor (HGF) receptor, MET, which was
found in four of eighteen (22%) resistant NSCLC (Engelman et al,
2007). The majority of the amplifications were found in metastatic
lesions, suggesting that Met may be involved in the development of
metastases as well as acquired resistance to TKI therapy.
Met plays a critical role in cancer, liver and kidney regeneration
and mammary gland development, including cell proliferation,
motility, invasion and branching tubulogenesis (Yang et al, 1995;
Rosario and Birchmeier, 2003; Gao and Vande Woude, 2005; Gao
et al, 2005; Desiderio, 2007; Sattler and Salgia, 2007). Met is present
in all tissue types, and activation of Met by its ligand, HGF, leads to
the activation of several signalling pathways that coordinate to
achieve Met-dependent cellular functions. In normal cells, Met
localises predominantly at the plasma membrane; however, in the
germinal tissue layer of normal colon, skin and testis, and in
cancerous tissue, both cytoplasmic and nuclear localisation have
been observed (Pozner-Moulis et al, 2006). Gain-of-function
mutations, overexpression or amplification of MET have been
identified and are associated with tumour growth and metastasis
(Ma et al, 2003; Lengyel et al, 2005; Kong-Beltran et al, 2006).
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sAlthough a small fraction of NSCLC patients (B10%) have major
objective responses to EGFR-based therapy, the majority of NSCLC
patients do not respond to EGFR-targeted therapies. Thus, there is a
pressing clinical need for the identification of new drug targets and
new treatment strategies. It is known that EGFR signalling is
modulated by other receptor tyrosine kinases (RTKs). For example,
it is well established that heterodimerisation with other ErbB family
receptors, Her2 and Her3, augments the oncogenic activities of EGFR
(Engelman et al, 2005, 2007; Arteaga, 2007). Furthermore, recent
evidence implicates Met in functional interactions with EGFR and
Her3 (Jo et al, 2000). As both the ErbB family of receptors and Met
are promising molecular targets for therapy of NSCLC, and with
evidence for functional interactions of these receptors, we have
explored the possibility that combined targeting of Met and one or
more ErbB family members may have therapeutic promise.
MATERIALS AND METHODS
Cell lines and other reagents
H441 and H1666 cells were purchased from ATCC (Manassas, VA,
USA) and were maintained in RPMI supplemented with 10% FBS,
sodium pyruvate, glutamine, penicillin and streptomycin in a 371C
incubator containing 5% CO2. 32D/Met cells were generously provided
to us by Dr Donald Bottaro from the National Cancer Institute,
Bethesda, MD, USA. These cells were maintained in RPMI medium
with 10% WEHI-conditioned medium to provide IL-3 (Day et al,
1999). PHA665752 (a small molecule TKI for Met) was a generous gift
from Pfizer (La Jolla, CA, USA), GW2974 (a dual small molecule TKI
for both EGFR and Her2) was purchased from Calbiochem
(Gibbstown, NJ, USA) and gefitinib (a small molecule TKI for EGFR)
was purchased from Biaffin GmbH & Co KG (Kassel, Germany). All
drugs were dissolved in DMSO to produce 20-mM stock solutions.
Rabbit anti-EGFR, mouse anti-EGFR, rabbit anti-Met, rabbit anti-Her2,
mouse anti-Her3, mouse IgG, goat antimouse HRP and goat antirabbit
HRP antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); mouse anti-Her2 was purchased from Labvision
(Fremont, CA, USA); rabbit anti-Her3, rabbit anti-Akt, rabbit anti-
phospho-Akt, rabbit anti-Erk1/2, rabbit anti-phospho-Erk1/2, mouse
antiphosphotyrosine, mouse anti-Stat3, rabbit antiphospho-Stat3
(Ser 727), rabbit antiphospho-Stat3 (Y705), mouse anti-Met, rabbit
antiphospho-Met (Y1234/1235), rabbit antiphospho-EGFR (Y1068),
rabbit antiphospho-EGFR (Y992), rabbit antiphospho-EGFR (845) and
rabbit anti-b-tubulin were purchased from Cell Signalling Technology
(Danvers, MA, USA); rabbit anti-Shc was purchased from Upstate Cell
Signalling Solutions (Billerica, MA, USA); and rabbit antiphospho-Shc
was purchased from Sigma-Aldrich (St Louis, MO, USA). Epidermal
growth factor (EGF), HGF and human phospho-RTK array kits were
purchased from R&D Systems (Minneapolis, MN, USA).
Receptor tyrosine kinase antibody array profile
Either 200mg (Figures 1A and 5A) or 500mg (Figure 2A) of whole
cell extracts were analysed on human phospho-RTK arrays from
R&D Systems according to the manufacturer’s recommendation.
Details of the protocol are provided in the Supplementary section.
Immunoprecipitation (IP) and immunoblot
For IP experiments, cells were incubated with either vehicle (0.5%
DMSO) or with indicated concentrations of GW2974 in 0.5%
DMSO containing cell media for 2h. Detailed protocols are in the
Supplementary section.
Cell proliferation assay
Cells were plated on 96-well plates in 50ml of media at a density of
3000cells per well for H441 cells or 10000cells per well for H1666
cells. Compounds were serially diluted into cell media as 2stocks
containing 1% DMSO, and 50ml of each dilution was added to the
wells in triplicate. After 5 days of incubation with the compounds,
cell survival was assessed by adding 10ml of WST-1 [2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H tetrazo-
lium] reagent (Roche Applied Sciences, Indianapolis, IN, USA) in
each well of a 96-well plate. After incubation for 3h, the plates were
read in a plate reader (Spectramax 250; Molecular Devices,
Sunnyvale, CA, USA) at 450nm. The zero time for cells with only
0.5% DMSO was also assessed for each plate and was subtracted
from the 5-day time points. The XLfit program (ID Business
Solutions, Parsippany, NJ, USA) was used to obtain and calculate
the GI50 curves for each compound using a non-linear regression
curve fit utilising Lavenburg–Marquardt algorithm. Each experi-
ment was performed a minimum of three times.
Hepatocyte growth factor activation
Cells were plated in 24-well plate in 750ml of starvation media (no
FBS and no IL-3 containing WEHI media) at a density of 510
6
cells per well for 32D/Met cells. After 2h of starvation, compounds
were serially diluted into cell starvation media as 2stocks
containing 1% DMSO, and 750ml of each dilution was added to the
wells. Details of the protocol are in the Supplementary section.
Lentivirus infection for Met shRNA
Met shRNA cloned in pLKO.1 puro vector (Engelman et al, 2007)
and empty pLKO.1 puro vector were used for lentivirus production
and infection in H441 cells as described (Engelman et al, 2007).
Stably infected cells were selected in 2mgml
1 of puromycin
(Promega, Madison, WI, USA).
RESULTS
Activation/overexpression of Met and resistance to
GW2974
Activation of multiple RTKs simultaneously can contribute to the
malignant phenotype in NSCLC. Thus, we used a RTK antibody
array that captures 42 receptors and was then probed with
antiphosphotyrosine to survey the activity of RTKs in NSCLC lines
H441 and H1666. These lines have wild-type (WT) EGFR.
Epidermal growth factor receptor and Her3 were highly activated
in H1666 cells, and EGFR, Her2 and Her3 in H441 cells
(Figure 1A). Both cell lines showed weak activation of MSPR and
DTK, and some Her4 activity was detected in H441 cells
(Figure 1A). In addition, H441 cells showed strong activation of
Met, consistent with earlier reports (Christensen et al, 2003),
whereas activated Met was not detected in H1666 cells (Figure 1A
and C).
With the potential importance of ErbB receptor inhibitors for
lung cancer treatment, and with multiple ErbB receptors activated
in these cell lines, we investigated their sensitivity to the dual
EGFR/Her2 kinase inhibitor GW2974 in proliferation assays.
GW2974 is an analogue of lapatinib with an enzymatic acitivity
of 0.007mM (compared with 0.012mM for lapatinib) for EGFR and
0.016mM (compared with 0.010mM for lapatinib) for Her2 (Rusnak
et al, 2001; Petrov et al, 2006). Cell growth was assessed after a
5-day continuous exposure to drug. H1666 cells showed high
sensitivity to GW2974 with an average GI50 of 0.1mM, compared
with H441, where the GI50 was in the micromolar range (6–9mM;
Figure 1B).
We examined the effects of GW2974 on signalling pathways both
at the receptor level and for downstream signalling components
(Figure 1C). GW2974 inhibited EGFR phosphorylation in H441
cells in a dose-dependent manner, although at micromolar
concentrations. Surprisingly, phospho-Met was also inhibited
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sby this compound at similar concentrations. Among potential
downstream signalling components, phospho-Erk1/2 was not
affected; however phospho-Akt, phospho-Stat3 and phospho-Shc
were inhibited by GW2974 in a dose-dependent manner
(Figure 1C). These data suggest that GW2974 affects Met activity,
directly or indirectly, in H441 cells. In contrast, in H1666 cells,
GW2974 inhibited phosphorylation of EGFR at submicromolar
concentrations, as well as downstream signalling molecules
including Akt, Erk1/2, and Stat3, consistent with its activity in
the proliferation assay. Interestingly, there was little basal
phosphorylation of EGFR at Y1068, or basal phosphorylation of
Met at Y1234/1235 in H1666 cells, and the baseline phosphoryla-
tion of these receptors and downstream signalling molecules were
only modestly inhibited by the drug (Figure 1C).
Constitutive activation of Met, Her2 and Her3 in H441 cells
is inhibited by GW2974
As NSCLC cells express many RTKs that could potentially
contribute to GW2974 sensitivity, we used RTK antibody capture
arrays to assess the effects of the drug on activation of 42 different
receptors in parallel (Figure 2A). Cells were serum starved and
then incubated with EGF for 10min in the presence or absence of
GW2974. Interestingly, Met, EGFR, Her2, Her3 and Ret were
basally activated in H441 cells, even under serum-deprivation
conditions. Stimulation with EGF further activated EGFR and Ret,
but not Met, Her2 or Her3 (Figure 2A). The activation of all these
receptors was inhibited by treatment with GW2974 (Figure 2A). A
lighter exposure of RTK array experiment is shown as Supple-
mentary Figure S1. Hence, EGFR, Met, Her2 and Her3 are all
activated in this cell line without exogenous EGF or HGF. These
data indicate constitutive activation of Met, Her2 and Her3 in this
cell line, and cross-talk among the ErbB family receptors and Met.
Immunoblot analysis of these extracts confirmed the RTK array
data showing constitutive activation of EGFR and Met and
inhibition by GW2974 (Figure 2B and C). Epidermal growth factor
was able to further activate the tyrosine phosphorylation of ErbB
receptors, and this effect is abrogated by the 2h treatment with
GW2974 (Bands around 175kDa correspond to ErbB receptors in
Figure 2B). Detailed investigation of the effect of EGF treatment
showed further phosphorylation of EGFR at Y845, but no further
activation at Y1068 of EGFR and Met were observed (Figure 2C).
Similarly, no further activation of Akt and Stat3 were observed
with EGF treatment, whereas Shc and Erk1/2 were further activated
by EGF treatment. Treatment of serum-deprived cells with
GW2974 for only 2h before EGF activation was sufficient to
inhibit phosphorylation of EGFR and Met similar to 5-day
continuous treatment with GW2974 in 10% serum (Figure 1C).
GW2974 also reduced downstream phosphorylation of Stat3, Shc
and Akt, although only reducing the EGF-dependent phosphoryla-
tion of Erk1/2 to baseline basal levels. Overall, these data show that
GW2974 inhibits the activation of downstream signalling induced
by EGF treatment.
GW2974 does not inhibit HGF-dependent activation of Met
in the absence of ErbB family receptors
The strong activation of members of both Met and ErbB families in
H441 cells suggests two possible mechanisms for the inhibitory
activity of GW2974 towards Met. The compound could work
directly through an off-target inhibition of Met in these cells.
Alternatively, ErbB receptors targeted by GW2974 may normally
promote phosphorylation of Met in these cells. This would be
consistent with recent studies suggesting receptor-level cross-talk
between ErbB receptors and Met (Radaeva et al, 1999; Jo et al,
2000; Engelman et al, 2007).
To determine whether GW2974 directly inhibits the activation of
Met, independent of its activity on EGFR and Her2, we incubated
serum-starved H441 cells with the Met ligand, HGF. GW2974
inhibited phosphorylation of Met in the absence or presence of
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Figure 1 Activation of Met and response to GW2974 in H441 cells. (A) Multiple RTKs are activated in H441 and H1666 cells in full serum conditions.
Whole cell extracts (200mg) were incubated with RTK capture array membranes. RTK activation was determined by probing with phosphotyrosine antibody
conjugated to horse-radish peroxidase. Paired spots correspond to 1: EGFR; 2: Her2; 3: Her3; 4: Her4; 5: Mer; 6: Met; 7: MSPR; 8: Flt3; 9: Ret; and 10: Dtk.
The four sets of duplicate spots at each corner of the RTK array membrane serve to orient and align the membrane to identify and correlate the positive set
of spots to individual RTKs. (B) Sensitivity of cell lines to GW2974. Cells were treated with indicated concentrations of GW2974 for 5 days, and cell
proliferation was measured using a WST-1 colorimetric assay. The GI50 of H1666 is 0.1mM compared with 8.6mM for H441 cells. Error bars represent s.d. of
three data sets. Representative data are shown from multiple experiments. (C) Dose-dependent inhibition of EGFR-dependent signalling in H1666 cells and
Met-dependent signalling in H441 cells by GW2974. Whole cell extracts were made from cells treated with GW2974 at indicated concentrations for 5 days
as in panel B, and subjected to immunoblotting with the indicated antibodies. Arrows indicate respective protein bands. b-Tubulin was used as a loading
control. GW2974 concentration in lanes 1: 1mM; 2: 0.5mM; 3: 0.25mM; 4: 0.125mM; 5: 0.0625mM;6 :0mM;7 :2 5mM; 8: 12.5mM; 9: 6.25mM; 10: 3.125mM; 11:
1.56mM and 12: 0mM.
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sexogenous HGF in a dose-dependent manner similar to its activity
in the presence of 10% foetal bovine serum (FBS) or EGF
(Compare Figure 3A with Figures 1 and 2). In addition, Met is
constitutively active in H441 cells (Figures 1 and 2), and we did not
observe any further phosphorylation in the presence of HGF
(Figure 3A). Furthermore, the activity of GW2974 on Met
phosphorylation was not influenced by the presence of HGF in
these cells. A small molecule inhibitor of Met (PHA665752,
referred to hereafter as PHA) was used as a positive control for
Met inhibition.
To directly evaluate possible off-target effects of GW2974 on
Met, we assayed activity on myeloid 32D cells stably transfected
with Met (32D/Met) (Day et al, 1999). These cells do not express
endogenous ErbB family receptors (EGFR, Her2, Her3 and Her4).
GW2974 did not strongly inhibit the HGF-dependent activation of
Met (Figure 3B, lanes 6–9), although there may be a marginal
reduction in Met activation at the higher concentration of
GW2974. Moreover, combination of the Met inhibitor, PHA, with
GW2974 yielded similar activity to PHA alone, and further
reduction in phosphorylation of Met was not observed
(Figure 3B, lanes 10–18). Another small molecule EGFR inhibitor,
gefitinib, did not inhibit Met activation in 32D/Met cells
(Figure 3B, lane 19 and Supplementary Figure S2). These data
suggest that, in H441 cells, the activity of GW2974 is due to the
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Figure 2 GW2974 inhibits constitutively activated Met, Her2 and Her3 in H441 cells. (A) GW2974 abrogates the activation of multiple receptors in
H441 cells. Cells were starved for 24h and then treated for 2h with GW2974 before incubation with EGF (100ngml
1) for 10min. Whole cell extracts
(500mg) were analysed on each RTK array membrane, and activation status of receptors was assessed using antiphosphotyrosine antibody and numbered as
in Figure 1A. 1: EGFR; 2: Her2; 3: Her3; 6: Met; 9: Ret; and 11: VEGFR-2. (B and C) GW2974 inhibits Met signalling and EGF-activated signalling. The extracts
analysed in panel A were analysed by immunoblotting with indicated antibodies. M and numbers in panel B indicate molecular weight marker for proteins.
b-Tubulin was used as a loading control.
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Figure 3 Cross-talk between Met and EGFR family receptors. GW2974 inhibits Met activation in a dose-dependent manner in H441 cells (A), but not in
the absence of EGFR family receptors in 32D/Met cells (B). (A) GW2974 inhibits Met activation in the presence or absence of HGF. Cells were serum
starved for 24h followed by treatment with either vehicle (DMSO) or GW2974 or a Met inhibitor (PHA) for 2h before activation with HGF (50ngml
1)
for 30min. Whole cell extracts were made and subjected to western blot with indicated antibodies. (B) GW2974 and gefitinib do not inhibit
HGF-dependent activation of Met in stably transfected 32D cells with Met (32D/Met). Cells were treated as in panel A. b-Tubulin was used as a loading
control.
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sinhibition of EGFR and/or Her2, which in turn affects the
phosphorylation of Met. This suggests an active cross-talk between
ErbB family receptors and Met.
Physical interaction of Her2 and Met is inhibited by
GW2974
As GW2974 had little impact on Met in cells lacking ErbB family
receptors, it is possible that, instead, the drug affects Met
activation in H441 cells by inhibiting EGFR and/or Her2, and
interfering secondarily with ErbB-dependent activation of Met.
One possibility is that Met forms a physical complex with one or
more ErbB family receptors. Indeed, Met coimmunoprecipitated
with Her2, indicating that they are found in a protein complex
(Figure 4A). This interaction was inhibited by GW2974 in a dose-
dependent fashion (compare lanes 3–4 with lane 2) paralleling
reduction in Met phosphorylation (Figure 1C). Similarly, Met was
coimmunoprecipitated with EGFR in H441 cells (Figure 4B).
However, in this case, GW2974 reduced, but did not completely
abrogate the interaction (compare lanes 7–8 with lanes 3–4).
These data suggest that the cross-talk of EGFR and Her2, with Met
is mediated through interactions in a protein complex, although
the nature of the interactions with EGFR and Her2 may be
different.
Downregulation of Met affects the activation of ErbB
family receptors
It has been shown previously that the downregulation of Met, in a
Met-overexpressing cell line with activating mutation in EGFR, did
not reduce the activation of EGFR or Her3, but did restore gefitinib
sensitivity (Engelman et al, 2007). We examined the effect of Met
downregulation using Met-specific shRNA in H441 cells, which
strongly reduced the expression of Met, but not EGFR, Her2 or
Her3 (Figure 5B). In RTK capture array analysis, not only the Met
phosphorylation but also the phosphorylation of ErbB family
receptors (EGFR, Her2 and Her3) and Ret (Figure 5A) were
reduced. Total tyrosine phosphorylation of immunoprecipitated
Her2 and Her3 was reduced with the expression of Met shRNA
(Figure 5C), consistent with the RTK capture array data
(Figure 5A). Further analysis of the effects of Met shRNA on ErbB
family receptors revealed that tyrosine phosphorylation sites in
ErbB receptors are affected differentially. Both TK domain (Y847)
as well as autophosphorylation sites (Y992, Y1068) of EGFR are
affected more, with concurrent inhibition of Erk1/2 and Akt
phosphorylation. In comparison, autophosphorylation sites of
Her2 (Y1289, Y1112) and kinase domain (Y877) site were only
modestly affected along with only marginal effect on Shc and no
apparent effect on Stat3 phosphorylation status. Similarly, Her3 at
Y1289 was less affected by the downregulation of Met (Figure 5B).
These data provide further evidence for the cross-talk of EGFR,
Her2 and Her3 with Met.
GW2974 inhibits wound healing in H441 cells
As Met interacts with both EGFR and Her2, and Met-dependent
signalling is inhibited by GW2974, we investigated the effects of
GW2974 on a process associated with Met biological activity,
wound healing. Earlier study showed that wound healing in
H441 cells is inhibited by treatment with the Met inhibitor PHA
(Christensen et al, 2003). GW2974 inhibited scratch wound healing
of H441 cells at a concentration that inhibits other Met-dependent
signalling processes (Supplementary Figure S3). The scratch
wound in cells treated with GW2974 (25mM) was not healed by
54h (Supplementary Figure S3H), whereas the scratch wound in
untreated cells healed by 24h in the presence of 10% FBS
(Supplementary Figure S3C). Similarly, the scratch wound of cells
expressing Met shRNA did not heal by 24h in the presence of 10%
FBS, whereas the scratch-wounded control cells were healed by
24h (Supplementary Figure S4B and D ).
Combination of inhibitors of Met with ErbB family
inhibitors
To explore the therapeutic implications of Met activation in the
treatment of NSCLC, we combined the Met inhibitor with either
gefitinib (Figure 6A) or GW2974 (Figure 6B) and monitored cell
growth in H441 cells, H441-pLKO.1 and H441-Met shRNA cells. A
fixed ratio of 1 was used for both PHA and GW2974 with
concentrations ranging from 0.125 to 3mM. Each data set is plotted
as a dose–response regression curve. Each drug alone was unable
to effectively inhibit the proliferation at concentrations used in this
study, but the combination of two drugs resulted in a synergistic
inhibition of proliferation. Importantly, the downregulation of Met
restored both gefitinib and GW2974 activities (Figure 6Aiii and
Biii). Western blot analysis indicates that GW2974 is more effective
in inhibiting phosphorylation of Her2, Her3, Stat3 and Shc in
H441-Met shRNA cells compared with control-infected H441-
pLKO.1 cells (Figure 6C) suggesting that Met is responsible for the
activation of EGF family receptor-dependent signalling and
resistance to GW2974 in H441 cells.
The combination of GW2974 with PHA yielded greater
synergistic inhibition at lower concentration of both drugs than
gefitinib with PHA for cell growth in H441-Met shRNA cells
(compare Figure 6Aiii with Figure 6Biii), suggesting that Met
directly affects the activation of EGFR in H441 cells. These data,
when combined with other data presented in this study, suggest
that simultaneous inhibition of multiple RTKs may be needed to
effectively abrogate cell growth.
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Figure 4 Met interacts with both EGFR and Her2, and the interaction is inhibited by GW2974. (A and B) Whole cell extracts were made from H441
cells treated with GW2974 for 2h or DMSO vehicle control. Extracts (1mg) were subjected to immunoprecipitation with anti-Her2 (A) or with anti-EGFR
(B) antibodies followed by immunoblotting with indicated antibodies. Immunoprecipitation with IgG was used as a negative control in each experiment.
Numbers on the side of panels indicate molecular weight marker. The middle panels of A and B are from the ErbB receptor region of the blot. (C) Whole
cell extracts were immunoblotted with anti-Met antibody to indicate equal amounts of Met in each treatment. b-Tubulin was used as a loading control.
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sDISCUSSION
In an effort to better understand potential druggable targets in
NSCLC, we screened several cell lines with RTK capture arrays.
These experiments revealed that, in H441 cells, the dominant RTK
activity was for EGFR, Her2, Her3 and Met receptors. The H441
cell line has been previously shown to be resistant to gefitinib and
cetuximab (Tracy et al, 2004; Mukohara et al, 2005). We found that
the activity of EGFR in these cells can be inhibited by the dual
EGFR and Her2 kinase inhibitor GW2974 at high micromolar
concentrations, which also affects the phosphorylation of Stat3,
Akt and Shc, but not Erk1/2. Unexpectedly, this inhibitor also
reduced the high level of basal Met phosphorylation. The
inhibition of Met by GW2974 seems to occur mainly by an
indirect mechanism, as this compound has no effect on Met
phosphorylation in Met-expressing 32D cells (32D/Met) that lack
EGFR and Her2 receptors. As Met is coimmunoprecipitated with
Her2 and EGFR, and this interaction is inhibited by GW2974, it is
suggested that the disruption of physical complexes among RTKs
is one possible mechanism. GW974 does have strong biological
activities that probably work through Met, including the inhibition
of wound healing after scratch injury of a cell monolayer.
Moreover, combinations of anti-Met and anti-ErbB drugs yielded
synergistic effects on cell proliferation and on downstream
signalling from these receptors.
Activated EGFR, Her2, Her3 and Her4 form heterodimers that
lead to cooperative and synergistic outputs. The close cooperativ-
ity of EGFR with Her2 has led to the development of other ErbB
receptor family inhibitor drugs including the dual EGFR/HER2
TKI lapatinib and therapeutic antibody, pertuzumab, which blocks
Her2 interactions with EGFR and Her3. These drugs are currently
in clinical trials (pertuzumab) or approved (lapatinib), showing
their promising activity in cancer. These receptors are also
modulated by direct association with other receptors (including
gp130), and by the impact of other receptors on functional
activation of growth factor propeptides by proteolytic processing
(e.g., Hb-EGF activation by G-protein-coupled receptors).
To date, there are no targeted therapies that are appropriate for
the majority of NSCLC patients who do not respond to erlotinib or
gefitinib. Presumably, these cancers are driven by the activation of
other signalling molecules beyond the EGFR. Some will have
mutations in other RTKs that would be hallmarks of sensitivity to
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Figure 5 Met shRNA downregulates ErbB family receptor activation. Whole cell extracts were made from control (H441-pLKO.1) and Met shRNA
(H441-Met shRNA) cells. (A) Whole cell extracts (200mg) were analysed on each RTK array membrane, and activation status of receptors was assessed
using antiphosphotyrosine antibody and numbered as in Figure 1A. 1: EGFR; 2: Her2; 3: Her3; 6: Met; 7: MSRP; and 9: Ret. (B) The cell extracts analysed in
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sRTK inhibitors with the appropriate action spectrum, whereas
others may be driven by mechanisms unrelated to RTKs. Profiling
tumours with RTK capture arrays may be very helpful in first-pass
analysis of tumours to identify active RTKs that may be susceptible
to treatment with the kinase inhibitors. For example, our finding
that H441 cells are sensitive to Met, and ErbB inhibitors could be
predicted based on the activity of these receptors determined by
RTK capture array (Figure 1).
Besides posing treatment challenges, the cross-interactivity of
RTKs potentially provides new treatment opportunities. This study
is focused on the interactions between two RTK families, ErbBs
and Met, that have overlapping functions in initiation and
progression of cancer. ErbBs are implicated in promoting
proliferation and survival, and Met has important roles in cell
motility and epithelial/mesenchymal transition. Our identification
of ErbB and Met signalling in a single lung cancer cell line, and the
involvement in responsiveness to ErbB and Met inhibitors is
consistent with other recent studies that highlighted functional
cooperation between these two receptor families (Bean et al, 2007;
Guo et al, 2008; Mueller et al, 2008; Shattuck et al, 2008; Yano et al,
2008). Interaction of these receptor families has been suggested for
years, based on the finding that Met is often co-overexpressed with
ErbBs in prostate and breast carcinoma. Hepatocyte growth factor
promotes motility and invasive behaviour by Her2 (Neu)-
transformed mammary epithelial cells (Khoury et al, 2005). A
recent phosphoproteomic screen for EGFR targets in glioblastoma
identified Met (Stommel et al, 2007).
Receptor tyrosine kinase antibody arrays used in this study
clearly indicated differences in receptor activation levels in two cell
lines with WT EGFR, which prompted us to investigate ErbB
family receptor inhibitors in NSCLC. In this study, we report the
activity of a lapatinib analogue, GW2974, which is a small molecule
dual TKI of EGFR/Her2. Lapatinib has shown preferential benefit
for Her2 amplified breast cancer patients compared with patients
with normal level of Her2 (Konecny et al, 2006). Although HER2 is
not commonly amplified in NSCLC, in approximately 2% of
NSCLC patients, an activating mutation similar to those observed
in EGFR has been reported in Her2. The response rate for lapatinib
alone in a randomised clinical trial for NSCLC was very low
(Smylie et al, 2007). We have shown that GW2974 does show a
high micromolar activity in H441 cells that carry WT EGFR and
constitutive activation and expression of Met. This activity is
similar to non-amplified Her2 in breast cancer (Konecny et al,
2006). However, we report a GW2974-sensitive lung cancer cell line
(H1666) that has normal level of both Her2 and Met, and does not
have activating mutation in EGFR. GW2974 was able to down-
regulate EGFR-dependent activation of Akt, Erk1/2, and had a
marginal effect on Stat3 in a dose-dependent fashion (Figure 1C).
This cell line has been shown to be resistant to gefitinib. Sensitivity
of this cell line to GW2974 is similar to its activity in Her2
amplified breast cancers. Further investigation is necessary to
understand the molecular mechanism for its response to this drug.
On the contrary, GW2974 downregulated Met-dependent
signalling in H441 and showed no effect on the phosphorylation
level of Erk1/2. Constitutive activation of Met, Her2 and Her3 even
in serum-starved cells suggests a ligand-independent activation of
these receptors. One possibility may be autocrine activation of
these receptors due to the expression of a ligand, such as EGF or
HGF etc. The expression of ligand by cancer cells has been
observed in many cases that often lead to drug resistance
bypassing a need for the overexpression or activating mutation
in oncogenes for cancer progression. A second possibility is the
transactivation by another receptor, for example, Met in H441 cells
that bypasses the need for ligand-dependent activation of EGFR,
Her2 and Her3 (Figures 1, 2, 5 and 6). GW2974 inhibited the
proliferation, Met-dependent activation of downstream signalling
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sand phosphorylation of Met in a dose-dependent manner in H441
cells, but did not downregulate the HGF-dependent activation of
Met in 32D/Met cells suggesting that in H441, there is an active
cross-talk between Met and ErbB receptors. However, the
inhibitory activity of GW2974 is observed at higher (micromolar)
concentration than is required normally for the inhibition of
EGFR/Her2-dependent signalling. In H441 cells, GW2974 only
inhibited the activation of EGFR, Her2 and Her3 at lower
concentrations, when Met was downregulated (Figure 6, compare
lane 2 with lane 6). Indeed, both Her2 and EGFR are able to
coimmunoprecipitate Met in H441 cells. The interaction of Met
with Her2 is inhibited by GW2974 in a dose-dependent fashion
similar to its activity towards Met-dependent signalling. However,
the interaction of Met with EGFR is of a different nature, as this
interaction is inhibited by GW2974 without showing any dose
dependence. For the first time, we have shown that the down-
regulation of Met by Met-specific shRNA leads to differential effect
on the tyrosine phosphorylation sites of EGFR, Her2 and Her3
(Figure 5) suggesting that Met plays a crucial role in activating
ErbB family receptors especially EGFR, as the activation of EGFR is
drastically affected with concomitant inhibition of Erk1/2 and Akt
activation. However, activation of Stat3 was not affected, and Shc is
only marginally affected by Met downregulation suggesting that it
is regulated by different mechanism. One such mechanism could
be ligand-dependent activation of Her2 and Her3 in these cells, as
the activation of both are downregulated by GW2974 in a dose-
dependent manner.
To explore the therapeutic implications of coactivation of RTKs,
we evaluated the combination of inhibitors for Met and ErbB
family receptors in H441 cells. As shown in Figure 6, either drug
alone was not very effective at inhibiting proliferation. However,
the combination of drugs was synergistic in inhibiting the
proliferation of cells very effectively. Interestingly, it is very clear
from regression curves that any small inhibition by PHA alone was
sufficient to effectively inhibit the cell growth when combined with
GW2974 at the lowest concentration of 0.125mM in Met shRNA
cells (Figure 6Biii), whereas this was not the case with PHA and
gefitinib in the same cells (Figure 6Aiii). This suggests that the
coactivation of multiple RTKs in cancer cells confer resistance to
single-agent therapy, but this resistance can easily be overcome by
simultaneously inhibiting several RTKs with rationally chosen
drug combinations. Similar observations were made recently in the
case of glioblastomas carrying activated EGFR and Met receptors
where simultaneous inhibition of EGFR (erlotinib) and Met
(SU11274) lead to the downregulation of PI3K pathway, and
reduced the size of colony formation in soft agar (Stommel et al,
2007). The single inhibition by single drug was less effective. Thus,
our study combined with other similar observations provides a
compelling evidence to effectively treat cancers by rationally
designed drug combinations.
The rapid pace of development of molecularly targeted anti-
cancer drugs creates a concomitant need for the development of
the best tools for matching the drugs to appropriate patients.
Phosphoproteomic analysis by RTK capture arrays may be a
valuable tool for identifying the subset of tumours with functional
receptor activation, regardless of mechanism. Similar arrays that
monitor the activity of intermediary signalling molecules through
their phosphorylation status provide one relatively inexpensive
tool for this purpose. The best analysis of tumour samples may
require a combination of proteomic, genetic, epigenetic and
functional characterisation.
The functional studies here led to the hypothesis that dual
targeting of ErbBs and Met may be very important in the treatment
of some human cancers. Ectopic signalling by members of each
receptor family are common in human cancer, and the receptor
systems have complementary functions in promoting growth,
survival and qualities associated with invasion and metastasis. This
study when combined with other studies provides compelling
support for the combination of these drugs in future clinical trials.
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